Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

That’s how long it takes, on average, for the pounds to begin creeping back after someone stops taking the world’s most ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

Everyone aspires to live a healthy life. The catch is that health is a moving target. It’s a challenge that changes as people ...

A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.